FRENCH NANOMEDICINE COMPANY NANOBIOTIX A WORLD LEADER

Paris headquartered company NANOBIOTIX is developing the injection of nanoparticles of hafnium oxide into cancerous tumors to enhance radiotherapy. The nanoparticles are about 50 nanometers in diameter, which is 3000th of the diameter of a human hair. Hafnium is also used as a radiation absorber in nuclear reactors. The size of the particles allows a substantial increase in doses of radiotherapy X-rays within the tumor without damaging healthy tissues. This treatment destroys the cancerous cells which reduces the size of the tumor and facilitates complete malignant tissue extraction through surgery. In June 2014, the successful completion of the clinical tests was presented at the American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago.